USP13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1068401	1.00	1/20
SCHEMBL29359604	1.00	1/20
SCHEMBL9921341	0.84	1/20
SCHEMBL13170963	0.84	1/20
SCHEMBL9921506	0.80	1/20
SCHEMBL13192047	0.80	1/20
SCHEMBL7469214	0.76	1/20
SCHEMBL9921355	0.71	1/20
SCHEMBL9921511	0.70	1/20
SCHEMBL9921345	0.69	1/20
SCHEMBL13192098	0.67	1/20
SCHEMBL17557755	0.67	1/20
SCHEMBL9921343	0.67	1/20
SCHEMBL13191867	0.67	1/20
SCHEMBL9921508	0.65	1/20
SCHEMBL22745068	0.64	1/20
SCHEMBL9921342	0.64	1/20
SCHEMBL9921352	0.64	1/20
SCHEMBL9921353	0.64	1/20
SCHEMBL13191858	0.64	1/20

Clinical trials — most relevant to USP13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas	nan	RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	nan	APPROVED_FOR_MARKETING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
ADAPT: Efficacy of a Dietary Supplement During and After Exercise	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a USP13 binder may also engage these)

Protein	Name	Similarity
E1BMF7	—	1.000	E1BMF7 →
Q5BKP2	—	1.000	Q5BKP2 →
E1BY77	—	1.000	E1BY77 →
F1QFS9	—	1.000	F1QFS9 →
F6V6I0	—	0.995	F6V6I0 →
Q8L6Y1	—	0.990	Q8L6Y1 →
P40826	—	0.989	P40826 →
USP14	Ubiquitin carboxyl-terminal hydrolase 14	0.989	landscape →
Q5R407	—	0.988	Q5R407 →
Q92353	—	0.988	Q92353 →
USP7	Ubiquitin carboxyl-terminal hydrolase 7	0.988	landscape →
Q6U7I1	—	0.988	Q6U7I1 →
Q4VSI4	—	0.987	Q4VSI4 →
P60051	—	0.987	P60051 →
Q0IIF7	—	0.987	Q0IIF7 →
A1DFN6	—	0.987	A1DFN6 →
A2QW83	—	0.987	A2QW83 →
Q5BBL5	—	0.986	Q5BBL5 →
A1CEK7	—	0.986	A1CEK7 →
P54201	—	0.985	P54201 →
Q0CJU7	—	0.985	Q0CJU7 →
Q84WC6	—	0.985	Q84WC6 →
Q9UTT1	—	0.984	Q9UTT1 →
Q9JMA1	—	0.984	Q9JMA1 →
USP5	Ubiquitin carboxyl-terminal hydrolase 5	0.983	landscape →
Q09879	—	0.983	Q09879 →
Q949Y0	—	0.983	Q949Y0 →
P56399	—	0.983	P56399 →
Q0UPL5	—	0.983	Q0UPL5 →
Q2GSV2	—	0.982	Q2GSV2 →